Furthermore, research involving children with epilepsy demonstrated that treatment with valproate led to a significant decrease in serum levels of C–C motif ligand 2 (CCL2), a chemokine associated with inflammation, without altering levels of interleukin-1 beta (IL-1β) [43]. The gene discussed is CCL2; the disease is epilepsy.